The product is priced at 95% below the brand-name cost. Ease of adoption. The product is FDA-designated as interchangeable and supported by innovative prescriber and patient engagement programs to ...

MedImpact expands access and affordability across healthcare with a low-cost alternative to one of the most prescribed and expensive biologics in the US SAN DIEGO, February 12, 2026--(BUSINESS ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira(R) (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (Adalumymab-ryvk), ...

The report reviews the challenge of ASP erosion in Medicare Part B and policy solutions that could ensure patients have access to biosimilars.

To combat rising costs, BCBSM installed a multi-year cost-cutting initiative to slice $600 million off its total spend, which has resulted in hundreds of job losses at the insurer. A total of 1,300 ...

AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and completing the VOLITE skin quality aesthetics trial to bolster its ...

The insurer said it reduced administrative costs, adjusted prices and benefited from investment gains. But payouts for member care and benefits rose.

CVS Health Inc. (NYSE: CVS) on Thursday said it is taking additional steps to lower prescription drug costs by expanding access to biosimilar medications, announcing new formulary changes that will ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.